NovaBay aganocides featured in EyeWorld

In an article in the May issue of EyeWorld, the newsmagazine of the American Society of Cataract and Refractive Surgery, NovaBay Pharmaceuticals (NYSE AMEX:NBY) CEO Dr. Ron Najafi and other members of his ophthalmology team discuss the ability of the company’s topical aganocide compounds to kill bacteria, viruses and fungi without developing drug resistance.

Aganocides may one day be used for a variety of dermatologic, ophthalmic, and urologic surface infections.

A copy of the article can be accessed here.